Biotech entity
pharma accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. Aparna Thakur is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. Their average consequence score of 7.3 runs above the beat's 6.2 for that window.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 34 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. Aparna Thakur is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. Their average consequence score of 7.3 runs above the beat's 6.2 for that window. They are less corroborated than the beat average, carrying 2.3 original sources each against 3.8 for the same window. That works out to roughly 0.1 stories per week across a 160-day span. We currently track 3 Biotech stories that mention Bayer, published between February 18, 2026 and July 27, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 626 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Bayer. Shared-story counts are live from our verified record — not editorial picks.
End of Certainty Period
The 21-year structured resolution period is slated to conclude.
Phase III Initiation
First patient dosed in the pivotal Phase III clinical trial for endometriosis.
$7.25B Settlement Announced
Bayer agrees to a new $7.25 billion deal with a 21-year certainty plan.
Phase II Completion
Positive results from Phase II studies demonstrate pain reduction and safety.
Initial $10B Settlement
Bayer announces a massive settlement to resolve current claims, but future liability remains.
Licensing Agreement
Hope Medicine acquires global rights for HMI-115 from Bayer.
Monsanto Acquisition
Bayer completes $63 billion acquisition of Monsanto, inheriting Roundup litigation.
A new DelveInsight forecast projects a 47% CAGR for the Alport syndrome market through 2036, fueled by a pipeline of gene and targeted therapies. The report highlights ELX-02 from Eloxx as a potential first-mover gene therapy with an 8-week dosing interval, while big pharma players like Bayer and Novartis advance competitors.
Source: prnewswire.com · finanznachrichten.de
Hope Medicine has officially initiated its Phase III clinical trial for endometriosis, dosing the first patient with HMI-115. This milestone marks a significant advancement in the development of a first-in-class prolactin receptor antagonist designed to address the high unmet need in women's health.
Bayer has reached a $7.25 billion settlement agreement to resolve long-standing litigation surrounding its Roundup herbicide. The deal includes a 21-year framework designed to provide legal and financial certainty for the company following years of costly courtroom battles.
Bayer is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
